Samsung Biologics Co.,Ltd. (KRX:207940)

South Korea · Delayed Price · Currency is KRW

1,641,000

-39,000 (-2.32%)

At close: Dec 5, 2025

Revenue by Geography

Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2015 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2015 - 2020
Domestic Revenue	144.43B	135.18B	Log In	Log In	Log In	Upgrade
Europe Revenue	3,058.61B	2,963.25B	Log In	Log In	Log In	Upgrade
USA Revenue	1,549.84B	1,174.14B	Log In	Log In	Log In	Upgrade
Other Geographic Revenue	278.82B	274.75B	Log In	Log In	Log In	Upgrade

Revenue Breakdown

Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	2014 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2014 - 2019
Contract Development and Manufacturing Organization (CDMO) Revenue	3,009.62B	Log In	Log In	Log In	Upgrade
Biopharmaceutical Development and Commercialization Revenue	1,537.70B	Log In	Log In	Log In	Upgrade

Revenue Breakdown 2

Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2015 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2015 - 2020
Product Revenue	4,793.03B	4,165.07B	Log In	Log In	Log In	Upgrade
Other Revenue	238.67B	382.25B	Log In	Log In	Log In	Upgrade

EBIT

Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	2014 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2014 - 2019
Contract Development and Manufacturing Organization (CDMO) Operating Profit	1,119.36B	Log In	Log In	Log In	Upgrade
Biopharmaceutical Development and Commercialization Operating Profit	200.69B	Log In	Log In	Log In	Upgrade